Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem BioAssay

Items: 7

1.

Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.

Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M, Chen Z, Xu W, Roberts H, Shepherd FA, Tsao MS, Reisman D.

Oncogene. 2011 Jul 21;30(29):3295-304. doi: 10.1038/onc.2011.81. Epub 2011 Apr 11.

2.

Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy.

Gramling S, Rogers C, Liu G, Reisman D.

Oncogene. 2011 Jul 21;30(29):3289-94. doi: 10.1038/onc.2011.80. Epub 2011 Apr 11.

3.

The SWI/SNF complex and cancer.

Reisman D, Glaros S, Thompson EA.

Oncogene. 2009 Apr 9;28(14):1653-68. doi: 10.1038/onc.2009.4. Epub 2009 Feb 23. Review.

PMID:
19234488
4.

The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.

Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D.

Oncogene. 2007 Oct 25;26(49):7058-66. Epub 2007 Jun 4.

PMID:
17546055
5.

Role for Brm in cell growth control.

Coisy-Quivy M, Disson O, Roure V, Muchardt C, Blanchard JM, Dantonel JC.

Cancer Res. 2006 May 15;66(10):5069-76.

6.
7.

Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha).

Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M.

EMBO J. 1998 Dec 1;17(23):6979-91.

Supplemental Content

Support Center